Eric J. Olson

Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease

W. Hiatt, J. Lepore, E. Hu, 2014, Vascular medicine.

Lipid Effects of Peroxisome Proliferator-Activated Receptor-&Dgr; Agonist GW501516 in Subjects With Low High-Density Lipoprotein Cholesterol: Characteristics of Metabolic Syndrome

D. Sprecher, G. Pearce, N. Jones, 2012, Arteriosclerosis, thrombosis, and vascular biology.

Apolipoprotein B-100–Containing Lipoprotein Metabolism in Subjects With Lipoprotein Lipase Gene Mutations

A. Lichtenstein, E. Schaefer, D. Sprecher, 2012, Arteriosclerosis, thrombosis, and vascular biology.

Clinical and Population Studies Apolipoprotein B100 – Containing Lipoprotein Metabolism in Subjects With Lipoprotein Lipase Gene Mutations

A. Lichtenstein, E. Schaefer, D. Sprecher, 2012 .

A Randomized, Placebo‐Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High‐Density Lipoprotein Cholesterol in Subjects With Dyslipidemia

F. Gao, D. Sprecher, J. Lepore, 2019, Clinical pharmacology in drug development.

Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men

T. Willson, P. Hegde, S. O’Rahilly, 2008, Diabetes.

HDL-C Response Variability to Niacin ER in US Adults

Jeffery K. Allen, K. Lowe, J. Christian, 2013, Cholesterol.

Idiopathic Pulmonary Fibrosis: Impact of Angiotensin Converting Enzyme Inhibitors and HMG-CoA Reductase Inhibitor s on Survival

P. Decker, W. W. Douglas, Eric J. Olson, 2003 .